What is the share price of ZIM Laboratories Ltd (ZIMLAB) today?
The share price of ZIMLAB as on 13th February 2026 is ₹71.23. The stock prices are volatile and keep changing through the day depending upon various factors and market conditions.What is the return on ZIM Laboratories Ltd (ZIMLAB) share?
The past returns of ZIM Laboratories Ltd (ZIMLAB) share are- Past 1 week: -0.34%
- Past 1 month: -3.33%
- Past 3 months: -3.05%
- Past 6 months: -7.43%
- Past 1 year: -26.78%
- Past 3 years: -10.40%
- Past 5 years: -36.48%
What are the peers or stocks similar to ZIM Laboratories Ltd (ZIMLAB)?
The peers or stocks similar to ZIM Laboratories Ltd (ZIMLAB) include:What is the market cap of ZIM Laboratories Ltd (ZIMLAB) share?
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of ZIM Laboratories Ltd (ZIMLAB) is ₹347.15 Cr as of 13th February 2026.What is the 52 week high and low of ZIM Laboratories Ltd (ZIMLAB) share?
The 52-week high of ZIM Laboratories Ltd (ZIMLAB) is ₹127 and the 52-week low is ₹65.52.What is the PE and PB ratio of ZIM Laboratories Ltd (ZIMLAB) stock?
The P/E (price-to-earnings) ratio of ZIM Laboratories Ltd (ZIMLAB) is 28.55. The P/B (price-to-book) ratio is 1.38.Which sector does ZIM Laboratories Ltd (ZIMLAB) belong to?
ZIM Laboratories Ltd (ZIMLAB) belongs to the Health Care sector & Pharmaceuticals sub-sector.How to buy ZIM Laboratories Ltd (ZIMLAB) shares?
You can directly buy ZIM Laboratories Ltd (ZIMLAB) shares on Tickertape. Simply sign up, connect your demat account and place your order.
ZIM Laboratories Ltd
ZIMLAB Share Price
71.234.80% (-3.59)
High
—
—
Low
—
—
Returns
—
—
1D
1W
1M
1Y
5Y
Max
SIP
1D
1W
1M
1Y
5Y
Max
SIP
ZIMLAB Stock Scorecard
Performance
LowHasn't fared well - amongst the low performers
Valuation
HighSeems to be overvalued vs the market average
Growth
AvgFinancials growth has been moderate for a few years
Profitability
AvgAverage profitability - not good, not bad
Entry point
AvgThe stock is not in the overbought zone
Red flags
LowNo red flag found
How to use scorecard? Learn more
ZIMLAB Performance & Key Metrics
ZIMLAB Performance & Key Metrics
| No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
|---|---|---|
| 49.81 | 1.38 | — |
| Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
|---|---|---|
| 35.82 | 5.68 | 0.60% |
ZIMLAB Analyst Ratings & Forecast
—
Analyst Ratings data is currently unavailable for this stockPrice Upside
Earnings Growth
Rev. Growth
ZIMLAB Company Profile
ZIM Laboratories Limited is a pharmaceutical company. The Company develops, manufactures and supplies oral, solid differentiated generic pharmaceutical formulations and pre-formulation intermediaries (PFI) in various therapeutic segments.
SUNPHARMA
PE Ratio
37.27
37.27
1Y Return
2.80%
2.80%
Buy Reco %
94.44
94.44
TORNTPHARM
PE Ratio
72.21
72.21
1Y Return
32.65%
32.65%
Buy Reco %
76.92
76.92
CIPLA
PE Ratio
20.40
20.40
1Y Return
9.55%
9.55%
Buy Reco %
56.25
56.25
DRREDDY
PE Ratio
18.67
18.67
1Y Return
3.64%
3.64%
Buy Reco %
51.61
51.61
LUPIN
PE Ratio
30.63
30.63
1Y Return
7.01%
7.01%
Buy Reco %
72.22
72.22
ZIMLAB Sentiment Analysis
ZIMLAB Sentiment Analysis
New
Crisp summary & key insights to decode earnings calls instantly
ZIMLAB Stock Summary · November 2025
In the recent earnings call, management highlighted a robust performance in the Pharma segment, which accounted for 83% of total revenue, while the nutraceutical segment faced challenges due to deferred domestic orders. The company is actively pursuing EU-GMP accreditation, with an audit scheduled for March 2026, and is implementing operational adjustments to ensure business continuity and mitigate supply chain disruptions. Despite a net loss of INR 4 million, improved cost management and a strong order backlog foster optimism for revenue growth of 20% to 25% in the upcoming fiscal year. Strategic product launches, including Tamsulosin and Dimethyl Fumarate, are anticipated to enhance market positioning and profitability, while ongoing compliance efforts aim to address previous regulatory challenges. Overall, the sentiment reflects confidence in overcoming short-term hurdles and achieving improved performance in the latter half of the fiscal year.
ZIMLAB Stock Growth Drivers
ZIMLAB Stock Growth Drivers
7Progress in EU-GMP Remediation
ZIM Laboratories Limited has made significant strides in its EU-GMP remediation efforts, emphasizing its commitment
Financial Performance and Growth in Pharma Segment
In the second quarter of FY '26, ZIM Laboratories reported a total operating income of
ZIMLAB Stock Challenges
ZIMLAB Stock Challenges
4Decline in Nutraceutical Segment Performance
The nutraceutical segment of ZIM Laboratories has experienced a significant decline in revenue, dropping from
Challenges in NIP Product Sales
Sales of NIP products have drastically decreased from INR 12-15 crores per quarter in FY
ZIMLAB Forecast
ZIMLAB Forecasts
Forecast data is currently unavailable
Forecast data is currently unavailable
Price
Price Upside
Revenue
Revenue Growth
Earnings
Earnings Per Share
ZIMLAB
ZIMLAB
Income
Balance Sheet
Cash Flow
Annual Normal View
ZIMLAB Income Statement
ZIMLAB Income Statement
Annual Normal View
| Financial Year | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | TTM | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 239.86 | 282.09 | 337.42 | 282.26 | 309.60 | 337.83 | 404.94 | 372.60 | 384.81 | 384.78 | ||||||||||
Raw Materials | 118.55 | 141.79 | 159.63 | 149.54 | 159.74 | 170.02 | 182.37 | 185.49 | 166.58 | 340.45 | ||||||||||
| Power & Fuel Cost | 5.35 | 5.75 | 7.19 | 7.47 | 7.04 | 9.14 | 11.09 | 13.47 | 17.39 | |||||||||||
| Employee Cost | 33.00 | 40.80 | 48.26 | 35.35 | 35.76 | 40.07 | 49.32 | 53.34 | 60.76 | |||||||||||
| Selling & Administrative Expenses | 36.64 | 42.21 | 67.10 | 40.72 | 43.06 | 53.79 | 54.02 | 49.83 | 50.56 | |||||||||||
| Operating & Other expenses | 9.98 | 7.47 | 11.16 | 22.05 | 27.08 | 19.43 | 49.73 | 23.96 | 40.02 | |||||||||||
EBITDA | 36.34 | 44.07 | 44.08 | 27.13 | 36.92 | 45.38 | 58.41 | 46.51 | 49.50 | 44.33 | ||||||||||
| Depreciation/Amortization | 9.02 | 9.79 | 11.42 | 14.41 | 15.79 | 16.03 | 17.47 | 15.95 | 20.11 | 20.16 | ||||||||||
| PBIT | 27.32 | 34.28 | 32.66 | 12.72 | 21.13 | 29.35 | 40.94 | 30.56 | 29.39 | 24.17 | ||||||||||
| Interest & Other Items | 9.82 | 9.34 | 10.59 | 12.65 | 10.90 | 8.31 | 5.58 | 6.92 | 11.39 | 12.80 | ||||||||||
| PBT | 17.50 | 24.94 | 22.07 | 0.07 | 10.23 | 21.04 | 35.36 | 23.64 | 18.00 | 11.37 | ||||||||||
| Taxes & Other Items | -1.09 | 5.82 | 6.72 | -3.22 | 2.91 | 6.49 | 10.92 | 6.39 | 5.84 | 4.40 | ||||||||||
| Net Income | 18.59 | 19.12 | 15.35 | 3.29 | 7.32 | 14.55 | 24.44 | 17.25 | 12.16 | 6.97 | ||||||||||
| EPS | 0.43 | 0.44 | 0.35 | 0.08 | 0.17 | 0.33 | 1.00 | 3.54 | 2.50 | 1.43 | ||||||||||
| DPS | 0.06 | 0.06 | 0.06 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||||||
| Payout ratio | 0.13 | 0.13 | 0.16 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
ZIMLAB Company Updates
FY 2026FY 2026
Investor Presentation
Feb 11PDF
Nov 12PDF
Aug 7PDF
ZIMLAB Stock Peers
ZIMLAB Past Performance & Peer Comparison
ZIMLAB Past Performance & Peer Comparison
Comparing 3 stocks from
Health CarePharmaceuticals
Compare valuation on Screener
Health CarePharmaceuticals
Valuation
Technical
Forecast
Compare valuation on Screener| Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
|---|---|---|---|
| ZIM Laboratories Ltd | 28.55 | 1.38 | — |
| Sun Pharmaceutical Industries Ltd | 37.27 | 5.62 | 0.94% |
| Torrent Pharmaceuticals Ltd | 72.21 | 18.18 | 0.78% |
| Cipla Ltd | 20.40 | 3.44 | 1.20% |
ZIMLAB Stock Price Comparison
Compare ZIMLAB with any stock or ETFCompare ZIMLAB with any stock or ETF
ZIMLAB
ZIMLAB Holdings
ZIMLAB Shareholdings
ZIMLAB Promoter Holdings Trend
ZIMLAB Promoter Holdings Trend
Total Promoter Holding
Increasing promoter holding is considered good and reflects management’s positive view about the future outlook
In last 6 months, promoter holding in the company has almost stayed constant
Low Pledged Promoter Holding
Lower pledged promoter holdings is considered better
Pledged promoter holdings is insignificant
ZIMLAB Institutional Holdings Trend
ZIMLAB Institutional Holdings Trend
Total Retail Holding
Increasing retail holding can be considered bad as it can reflect that institutions and promoters are selling their stake which is being absorbed by retail investors.
In last 3 months, retail holding in the company has almost stayed constant
Foreign Institutional Holding
Foreign Institutional Holding is quantum of stock held by foreign large-quantities-trading entities. Increasing value indicates growing support and comfort for the stock
In last 3 months, foreign institutional holding of the company has almost stayed constant
ZIMLAB Shareholding Pattern
ZIMLAB Shareholding Pattern
ZIMLAB Shareholding History
ZIMLAB Shareholding History
Foreign Institutions
smallcases containing ZIMLAB stock
smallcases containing ZIMLAB stock
Looks like this stock is not in any smallcase yet.
ZIMLAB Events
ZIMLAB Events
ZIMLAB Dividend Trend
No Dividends
Dividends are the portion of earnings that a company distributes to all its shareholders every year
ZIMLAB has not given any dividends in last 5 years
Dividends
Corp. Actions
Announcements
Legal Orders
Dividends
ZIMLAB Dividend Trend
No Dividends
Dividends are the portion of earnings that a company distributes to all its shareholders every year
ZIMLAB has not given any dividends in last 5 years
ZIMLAB Upcoming Dividends
ZIMLAB Upcoming Dividends
No upcoming dividends are available
ZIMLAB Past Dividends
ZIMLAB Past Dividends
Cash Dividend
Ex DateEx DateSep 19, 2019
Final
Final | Div/Share: ₹0.50
Dividend/Share
₹0.50
Ex DateEx Date
Sep 19, 2019
Cash Dividend
Ex DateEx DateSep 3, 2018
Final
Final | Div/Share: ₹1.00
Dividend/Share
₹1.00
Ex DateEx Date
Sep 3, 2018
ZIMLAB Stock News & Opinions
ZIMLAB Stock News & Opinions
Articles & Videos
Earnings
Zim Laboratories consolidated net profit rises 10.00% in the December 2025 quarter
Net profit of Zim Laboratories rose 10.00% to Rs 4.40 crore in the quarter ended December 2025 as against Rs 4.00 crore during the previous quarter ended December 2024. Sales rose 12.80% to Rs 108.66 crore in the quarter ended December 2025 as against Rs 96.33 crore during the previous quarter ended December 2024. ParticularsQuarter EndedDec. 2025Dec. 2024% Var. Sales108.6696.33 13 OPM %11.7912.01 - PBDT11.0810.58 5 PBT6.055.70 6 NP4.404.00 10 Powered by Capital Market - Live
3 days agoCapital Market - Live
Corporate
Zim Laboratories announces board meeting date
Zim Laboratories will hold a meeting of the Board of Directors of the Company on 11 February 2026.Powered by Capital Market - Live
1 week agoCapital Market - Live
Corporate
Zim Laboratories to conduct EGM
Zim Laboratories announced that an Extra Ordinary General Meeting (EGM) of the Company will be held on 16 February 2026.Powered by Capital Market - Live
3 weeks agoCapital Market - Live
Corporate
Zim Laboratories announces board meeting date
Zim Laboratories will hold a meeting of the Board of Directors of the Company on 21 January 2026.Powered by Capital Market - Live
4 weeks agoCapital Market - Live
Spotlight
Zim Laboratories gets CDSCO nod for Naproxen'Esomeprazole combination capsule
The formulation has been developed using the company's proprietary drug delivery technologies, combining naproxen delayed-release minitablets and esomeprazole pellets in a single hard gelatin capsule. Zim said the platform offers a differentiated, patient-friendly delivery system and forms part of its New Innovative Product (NIP) pipeline. The FDC is indicated for adults for the symptomatic treatment of osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis, and for reducing the risk of NSAID-associated gastric and duodenal ulcers. Zim Laboratories stated that the approval strengthens its presence in the pain-management and gastro-protective segments. The company has already signed a commercial supply agreement with an Indian pharmaceutical firm and is working toward launching the product in India in FY 2026'27 (FY27). Zim added that the approval aligns with its strategy of developing innovative, differentiated generics using advanced formulation technologies. ZIM Laboratories is a research-driven pharmaceutical company that develops, manufactures, and supplies differentiated generic products in oral solid dosage forms across key therapeutic segments. The company's consolidated net profit dropped 117.6% to Rs 0.42 crore as revenue fell 3.7% to Rs 88.71 crore in the quarter ended September 2025 as compared with the previous quarter ended September 2024. The scrip rose 0.45% to Rs 71.15 on the BSE. Powered by Capital Market - Live
2 months agoCapital Market - Live
Earnings
Zim Laboratories reports consolidated net loss of Rs 0.42 crore in the September 2025 quarter
Net loss of Zim Laboratories reported to Rs 0.42 crore in the quarter ended September 2025 as against net profit of Rs 2.38 crore during the previous quarter ended September 2024. Sales declined 3.72% to Rs 88.71 crore in the quarter ended September 2025 as against Rs 92.14 crore during the previous quarter ended September 2024. ParticularsQuarter EndedSep. 2025Sep. 2024% Var. Sales88.7192.14 -4 OPM %6.4910.34 - PBDT4.647.96 -42 PBT-0.342.96 PL NP-0.422.38 PL Powered by Capital Market - Live
3 months agoCapital Market - Live
Corporate
Zim Laboratories to hold board meeting
Zim Laboratories will hold a meeting of the Board of Directors of the Company on 12 November 2025.Powered by Capital Market - Live
3 months agoCapital Market - Live
Earnings
Zim Laboratories reports consolidated net loss of Rs 1.87 crore in the June 2025 quarter
Net loss of Zim Laboratories reported to Rs 1.87 crore in the quarter ended June 2025 as against net profit of Rs 0.90 crore during the previous quarter ended June 2024. Sales declined 12.30% to Rs 71.76 crore in the quarter ended June 2025 as against Rs 81.82 crore during the previous quarter ended June 2024. ParticularsQuarter EndedJun. 2025Jun. 2024% Var. Sales71.7681.82 -12 OPM %5.949.83 - PBDT2.436.18 -61 PBT-2.431.23 PL NP-1.870.90 PL Powered by Capital Market - Live
6 months agoCapital Market - Live
Spotlight
Zim Laboratories Ltd leads losers in 'B' group
PSP Projects Ltd, BirlaNu Ltd, Kabra Extrusion Technik Ltd and Vishnu Chemicals Ltd are among the other losers in the BSE's 'B' group today, 04 August 2025.Zim Laboratories Ltd lost 19.98% to Rs 86.3 at 14:28 IST.The stock was the biggest loser in the BSE's 'B' group.On the BSE, 1.55 lakh shares were traded on the counter so far as against the average daily volumes of 14020 shares in the past one month.PSP Projects Ltd crashed 12.88% to Rs 661.7. The stock was the second biggest loser in 'B' group.On the BSE, 2.44 lakh shares were traded on the counter so far as against the average daily volumes of 5977 shares in the past one month.BirlaNu Ltd tumbled 11.26% to Rs 1979.45. The stock was the third biggest loser in 'B' group.On the BSE, 6240 shares were traded on the counter so far as against the average daily volumes of 739 shares in the past one month.Kabra Extrusion Technik Ltd pared 10.38% to Rs 260. The stock was the fourth biggest loser in 'B' group.On the BSE, 21920 shares were traded on the counter so far as against the average daily volumes of 7799 shares in the past one month.Vishnu Chemicals Ltd plummeted 9.74% to Rs 487.5. The stock was the fifth biggest loser in 'B' group.On the BSE, 55016 shares were traded on the counter so far as against the average daily volumes of 27317 shares in the past one month.Powered by Capital Market - Live
6 months agoCapital Market - Live
Corporate
Zim Laboratories to conduct board meeting
Zim Laboratories will hold a meeting of the Board of Directors of the Company on 7 August 2025.Powered by Capital Market - Live
6 months agoCapital Market - Live
Over the last 5 years, revenue has grown at a yearly rate of 6.39%, vs industry avg of 10.04%
Over the last 5 years, market share decreased from 0.11% to 0.09%
Over the last 5 years, net income has grown at a yearly rate of 29.88%, vs industry avg of 20.02%